D. E. Shaw & Co. Inc. Sells 210,999 Shares of CareDx, Inc (NASDAQ:CDNA)

D. E. Shaw & Co. Inc. lowered its position in CareDx, Inc (NASDAQ:CDNA - Free Report) by 15.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,149,228 shares of the company's stock after selling 210,999 shares during the quarter. D. E. Shaw & Co. Inc. owned 2.14% of CareDx worth $24,605,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in CDNA. Sterling Capital Management LLC lifted its holdings in CareDx by 771.2% in the 4th quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock worth $27,000 after buying an additional 1,126 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of CareDx by 553.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company's stock valued at $84,000 after purchasing an additional 3,322 shares in the last quarter. Plato Investment Management Ltd raised its stake in shares of CareDx by 34.1% in the 4th quarter. Plato Investment Management Ltd now owns 5,390 shares of the company's stock valued at $116,000 after purchasing an additional 1,370 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its stake in shares of CareDx by 41.5% in the 4th quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 9,343 shares of the company's stock valued at $200,000 after purchasing an additional 2,742 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of CareDx in the 4th quarter valued at about $208,000.

Insider Buying and Selling

In related news, Director Peter Maag sold 13,281 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $17.23, for a total value of $228,831.63. Following the completion of the transaction, the director now owns 316,743 shares of the company's stock, valued at approximately $5,457,481.89. This trade represents a 4.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Christine Cournoyer sold 29,136 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $15.96, for a total transaction of $465,010.56. Following the completion of the transaction, the director now directly owns 37,045 shares of the company's stock, valued at $591,238.20. This represents a 44.02% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 59,382 shares of company stock worth $934,509. Corporate insiders own 4.90% of the company's stock.

CareDx Stock Up 0.5%

NASDAQ CDNA traded up $0.08 on Thursday, hitting $16.10. The stock had a trading volume of 1,684,588 shares, compared to its average volume of 877,911. CareDx, Inc has a one year low of $12.90 and a one year high of $34.84. The stock has a market cap of $896.46 million, a price-to-earnings ratio of -5.96 and a beta of 2.27. The company's 50-day moving average is $17.68 and its two-hundred day moving average is $21.02.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported $0.09 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.03. The business had revenue of $84.69 million for the quarter, compared to analyst estimates of $84.56 million. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The business's revenue for the quarter was up 17.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.03) earnings per share. On average, sell-side analysts anticipate that CareDx, Inc will post -0.9 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on CDNA shares. Stephens restated an "overweight" rating and issued a $40.00 target price on shares of CareDx in a research note on Monday, May 5th. StockNews.com lowered shares of CareDx from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Wells Fargo & Company upgraded shares of CareDx from an "underweight" rating to an "equal weight" rating and dropped their price objective for the stock from $28.00 to $24.00 in a research note on Wednesday, January 15th. HC Wainwright reiterated a "neutral" rating and set a $25.00 price objective on shares of CareDx in a research note on Monday, May 5th. Finally, The Goldman Sachs Group dropped their price objective on shares of CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $30.33.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.